arGentis Pharmaceuticals Overview

  • Founded
  • 2005
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $500K
Latest Deal Amount
  • Investors
  • 1

arGentis Pharmaceuticals General Information

Description

Developer of a pharmaceutical platform intended to develop and commercialize treatments to improve the health and quality of life for targeted patient groups. The company's platform focuses on treating autoimmune diseases through the utilization of oral and trans-dermal compounds, enabling patients to recover quickly and prevent the further spread of various diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 875 West Poplar Avenue
  • Suite 23-241
  • Collierville, TN 38017
  • United States
+1 (901) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

arGentis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC $500K 000 Completed Generating Revenue
2. Early Stage VC 28-Mar-2008 00000 00000 Completed Generating Revenue
1. Angel (individual) 21-Jun-2007 $1M Completed Generating Revenue
To view arGentis Pharmaceuticals’s complete valuation and funding history, request access »

arGentis Pharmaceuticals Executive Team (12)

Name Title Board Seat Contact Info
Tom Davis Co-Founder, Chief Executive Officer and President
Krzysztof Appelt Ph.D Vice President and Chief Development Officer
Ralph Henderson Co-Founder, Chief Marketing Officer and Vice President of Business Development
Arnold Postlethwaite MD Co-Chief Medical Officer and Lead Researcher
Ed TBD Executive
You’re viewing 5 of 12 executive team members. Get the full list »

arGentis Pharmaceuticals Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innova Memphis Venture Capital Minority 000 0000 000000 0
To view arGentis Pharmaceuticals’s complete investors history, request access »